MK-801 potentiates antidystonic effects of clozapine but not of haloperidol in mutant dystonic hamsters

Brain Research

Volumn 769, Issue 2, 1997, Pages 296-302

  Richter, Angelika ^a   Löscher, Wolfgang ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Animal model; Catalepsy; Dystonia; Neuroleptic; NMDA receptor

Indexed keywords

CLOZAPINE; DIZOCILPINE; HALOPERIDOL;

ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; DYSTONIA; HAMSTER; HYPERACTIVITY; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-DYSKINESIA AGENTS; CATALEPSY; CLOZAPINE; CRICETINAE; DIZOCILPINE MALEATE; DRUG SYNERGISM; DYSTONIA; FEMALE; HALOPERIDOL; MALE; MUTATION; NEUROPROTECTIVE AGENTS;

EID: 0343924431     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00720-8     Document Type: Article

References (37)

1. Bardgett M.E., Wrona C.T., Newcomer J.W., Csernansky J.G. Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics. Eur. J. Pharmacol. 230:1993;245-250.
2. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272-276.
3. Greenamyre J.T. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J. Neural Transm. 91:1993;255-269.
4. Fahn S. Systemic therapy of dystonia. Can. J. Neurol. Sci. 14:1987;528-532.
5. Fredow G., Löscher W. Effects of pharmacological manipulation of GABAergic neurotransmission in a new mutant hamster model of paroxysmal dystonia. Eur. J. Pharmacol. 192:1991;207-219.
6. Hallett M. Physiology of basal ganglia disorders: an overview. Can. J. Neurol. Sci. 20:1993;177-183.
7. Kinon B.J., Lieberman J.A. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology. 124:1996;2-34.
8. Koek W., Woods J.H., Winger G.D. MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 245:1988;969-974.
9. Kulkarni S.K., Verma A. Glutamate-dopamine receptor interaction in neuropsychiatric disorders. Drugs Today. 27:1991;255-270.
10. A.E. Lang, Dopamine agonists and antagonists in the treatment of idiopathic dystonia, in: S. Fahn, C.D. Marsden, D.B. Calne (Eds.), Dystonia 2, Raven Press, New York, 1988, pp. 561-570.
11. B. Lannes, G. Micheletti, Glutamate-dopamine balance in the striatum: pre- and postsynaptic interactions, in: G. Percheron, J.S. McKenzie, J. Feger (Eds.), Advances in Behavioral Biology. The Basal Ganglia IV: New Ideas and Data on Structure and Function, Plenum Press, New York, 1994, pp. 475-489.
12. Liljequist S., Ossowska K., Grabowska Anden M., Anden N.E. Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice. Eur. J. Pharmacol. 195:1991;55-61.
13. Löscher W., Annies R., Hönack D. The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci. Lett. 128:1991;191-194.
14. Löscher W., Fisher J.E., Schmidt D., Fredow G., Hönack D., Iturrian W.B. The sz mutant hamster: a genetic model of epilepsy or of paroxysmal dystonia? Mov. Dis. 4:1989;219-232.
15. Löscher W., Fredow G. Effects of pharmacological manipulation of dopaminergic and cholinergic neurotransmission in genetically dystonic hamsters. Eur. J. Pharmacol. 213:1992;31-39.
16. Löscher W., Hönack D. The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems. Eur. J. Pharmacol. 215:1992;199-208.
17. Marsden C.D., Quinn N.P. The dystonia. Br. Med. J. 300:1990;139-143.
18. Maura G., Giardi A., Raiteri M. Release-regulating D-2 dopamine receptors are located on striatal glutamatergic nerve terminals. J. Pharmacol. Exp. Ther. 247:1988;680-684.
19. Mundinger F., Milios E. Erfahrungen mit Memantine bei der Behandlung schwerer spastischer und extrapyramidaler Bewegungsstörungen in Kombination mit der stereotaktischen Operation. Nervenarzt. 56:1985;106-109.
20. J.N. Nobrega, A. Richter, D. Jiwa, R. Raymond, W. Löscher, Autoradiographic analysis of NMDA receptor binding in dystonic hamster brains, Brain Res. in press.
21. Nobrega J.N., Richter A., Tozman N., Jiwa D., Löscher W. Quantitative autoradiography reveals regionally selective changes in dopamine D1 and D2 receptor binding in the genetically dystonic hamster. Neuroscience. 71:1996;927-936.
22. Overton P., Clark D. N-Methyl-D-aspartate increases the excitability of nigrostriatal dopamine terminals. Eur. J. Pharmacol. 201:1991;117-120.
23. Richter A., Fredow G., Löscher W. Antidystonic effects of the NMDA receptor antagonists memantine, MK-801 and CGP 37849 in a hamster model of paroxysmal dystonia. Neurosci. Lett. 133:1991;57-60.
24. Richter A., Löscher W. The atypical neuroleptic, clozapine, exerts antidystonic activity in a mutant hamster model. Comparison with haloperidol. Eur. J. Pharmacol. 242:1993;309-312.
25. Richter A., Löscher W., Löschmann P.-A. The AMPA receptor antagonist NBQX exerts antidystonic effects in an animal model of idiopathic dystonia. Eur. J. Pharmacol. 231:1993;287-291.
26. Rogawski M.A. The NMDA receptor: NMDA antagonists and epilepsy therapy. A status report. Drugs. 44:1992;279-292.
27. Schmidt C.J., Fadayel G.M. Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade. J. Pharmacol. Exp. Ther. 277:1996;1541-1549.
28. Schmidt W.J., Bubser M. Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol. Biochem. Behav. 32:1989;621-623.
29. Schmidt W.J., Bubser M., Hauber W. Behavioural pharmacology of glutamate in the basal ganglia. J. Neural Transm. (suppl.). 38:1992;65-89.
30. See R.E., Chapman M.A. Chronic haloperidol, but not clozapine, produces altered oral movements and increased extra cellular glutamate in rats. Eur. J. Pharmacol. 263:1994;269-276.
31. M. Segawa, Y. Nomura, Hereditary progressive dystonia with diurnal fluctuation and dopa-responsive dystonia: pathognomonic clinical features, in: M. Segawa, Y. Nomura (Eds.), Age-Related Dopamine-Dependent Disorders, Monogr. Neural Sci., vol. 15, Karger, Basel, 1995, pp. 10-24.
32. Starr M.S. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse. 19:1995;264-293.
33. Wahnschaffe U., Fredow G., Heintz P., Löscher W. Neuropathological studies in a mutant hamster model of paroxysmal dystonia. Mov. Dis. 5:1990;286-293.
34. Wedzony K., Czyrak A., Mackowiak M., Fijal K. The impact of a competitive and a non-competitive NMDA receptor antagonist on dopaminergic neurotransmission in the rat ventral tegmental area and substantia nigra. Naunyn-Schmiedeberg's Arch. Pharmacol. 353:1996;517-527.
35. Yamamoto B.K., Davy S. Dopaminergic modulation of glutamate release in the striatum as measured by microdialysis. J. Neurochem. 58:1992;1736-1742.
36. Yoshida Y., Tomoko O., Kawano K., Miyagishi T. Distinct sites of dopaminergic and glutamatergic regulation of haloperidol-induced catalepsy within the rat caudate-putamen. Brain Res. 639:1994;139-148.
37. Zipp F., Bürklin F., Stecker K., Baas H., Fisher P.-A. Lamotrigine in Parkinson's disease - a double blind study. J. Neural Transm. 10:1995;199-206.